Lipum Q2 report - One step back, one step forward
2023-08-31 13:41:00
Redeye provides a research update on Lipum following the Q2 report published by the company earlier today. We make some adjustments to our estimates following a higher cash burn than expected and the outcome of the recent rights issue. Accordingly, we slightly lower our fair value range (SEK4 – SEK32) with a revised base case valuation of SEK20 (22) as we continue to see significant upside potential in the stock.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/